Krista L. Dobo

Pfizer (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

24h-index1.8kcitations54works9.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Carcinogens and Genotoxicity Assessment(34), Computational Drug Discovery Methods(9), Effects and risks of endocrine disrupting chemicals(9), Water Treatment and Disinfection(8), Pesticide Exposure and Toxicity(6)

Publications54 total

Studies addressing potential bioactivation and genotoxicity liabilities of the <i>N</i> -nitroso derivative of the antidepressant paroxetine
Xenobiotica·2025· 1 cited
Drug Substance and Drug Product Workflows for Quality Risk Management for the Presence of Nitrosamines in Medicines
Organic Process Research & Development·2025· 5 citedOpen Access
N-Nitrosamine drug substance related impurities (NDSRIs) – A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight &gt; 200 Da
Regulatory Toxicology and Pharmacology·2024· 11 cited
A Kinetic Model for Assessing Potential Nitrosamine Carcinogenicity
Chemical Research in Toxicology·2024· 5 cited
Evaluation of the nitrosamine impurities of <scp>ACE</scp> inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential
Environmental and Molecular Mutagenesis·2024· 10 citedOpen Access
N-nitrosamine safety assessments - Current challenges
Drug Metabolism and Pharmacokinetics·2024
A Case to Support the Continued Use of Rifampin in Clinical Drug–Drug Interaction Studies
Clinical Pharmacology & Therapeutics·2024· 2 cited
Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency
Chemical Research in Toxicology·2024· 43 cited
Strategies for Assessing Acceptable Intakes for Novel <i>N</i>-Nitrosamines Derived from Active Pharmaceutical Ingredients
Journal of Medicinal Chemistry·2022· 33 cited
Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product <i>N</i>-Nitrosamine Impurities
Chemical Research in Toxicology·2022· 80 citedOpen Access
Permitted daily exposure limits for noteworthy <i>N‐nitrosamines</i>
Environmental and Molecular Mutagenesis·2021· 66 citedOpen Access
Deriving Compound-Specific Exposure Limits for Chemicals Used in Pharmaceutical Synthesis: Challenges in Expert Decision-Making Exemplified Through a Case Study-Based Workshop
International Journal of Toxicology·2021· 3 cited
Management of pharmaceutical ICH M7 (Q)SAR predictions – The impact of model updates
Regulatory Toxicology and Pharmacology·2020· 31 citedOpen Access
<i>In Vivo</i> Mutagenicity Testing of Arylboronic Acids and Esters
Environmental and Molecular Mutagenesis·2019· 14 cited
Genetic toxicology in silico protocol
Regulatory Toxicology and Pharmacology·2019· 78 citedOpen Access
2‐Hydroxypyridine N‐Oxide is not genotoxic <i>in vivo</i>
Environmental and Molecular Mutagenesis·2019· 4 cited
Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses
Regulatory Toxicology and Pharmacology·2018· 31 citedOpen Access
A pharma-wide approach to address the genotoxicity prediction of primary aromatic amines
Computational Toxicology·2018· 26 cited
In silico toxicology protocols
Regulatory Toxicology and Pharmacology·2018· 234 citedOpen Access
2‐Hydroxypyridine‐N‐oxide (HOPO): Equivocal in the ames assay
Environmental and Molecular Mutagenesis·2018· 2 cited
page 1 of 3Next →

Frequent Co-authors

Michelle Kenyon(21), Joel P. Bercu(12), Susanne Glowienke(10), James Harvey(9), Robert A. Jolly(9), Wolfgang Muster(9), William C. Gunther(9), Laura Custer(8), Stephanie L. Coffing(8), Alexander Amberg(7), M. Vijayaraj Reddy(7), Andrew Teasdale(7), Angela White(7), Joerg Wichard(7), John Nicolette(7), Maik Schuler(7), Jennifer Cheung(7), Kevin P. Cross(6), Jacky Van Gompel(6), Naomi L. Kruhlak(6)